<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1012246388
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BENEFIX 2000 I.U. POWDER FOR SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        COAGULATION FACTOR IX RECOMBINANT HUMAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5018.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="WYETH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            WYETH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            WYETH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BeneFIX is an injectable clotting (coagulation) factor IX product that is produced by recombinant DNA technology. The active ingredient in BeneFIX is nonacog alfa. People who are born with haemophilia B (Christmas disease) lack sufficient factor IX to control bleeding. BeneFIX works by replacing factor IX in haemophilia B patients to enable their blood to clot.</p><p>&nbsp;</p><p>BeneFIX is used for the treatment and prevention of bleeding in patients with haemophilia&nbsp;B (congenital factor IX deficiency) in all age groups.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take BeneFIX:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to nonacog alfa or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to hamster proteins.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Talk to your doctor or pharmacist before using BeneFIX.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See your doctor immediately if your bleeding does not stop as expected.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions are possible. The product may contain traces of hamster proteins (see Do not take BeneFIX). Potentially life‑threatening anaphylactic reactions (severe allergic reactions) have occurred with factor IX products, including BeneFIX. Early signs of allergic reactions include difficulty breathing, shortness of breath, swelling, hives, itching, generalised urticaria, tightness of the chest, wheezing, low blood pressure, blurred vision and anaphylaxis (severe allergic reaction that can cause difficulty in swallowing and/or breathing, red or swollen face and/or hands).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If allergic or anaphylactic‑type reactions occur, <strong>stop the infusion immediately and contact a doctor or seek emergency medical care immediately</strong>. In case of severe allergic reactions, alternative therapy should be considered.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Activity‑neutralizing antibodies (inhibitors) are an uncommon event in patients who have received previous treatment with factor IX‑containing products. However, as with all factor IX products you should be carefully monitored for the development of factor IX inhibitors while being treated with BeneFIX.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research has shown a link between the occurrence of a factor IX inhibitor and allergic reactions. Therefore, if you experience allergic reactions such as those described above, you should be tested for the presence of an inhibitor. It should be noted that patients with a factor IX inhibitor may be at an increased risk of anaphylaxis during future treatment with BeneFIX.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The production of factor IX in the body is controlled by the factor IX gene. Patients who have specific mutations of their factor IX gene such as major deletion may be more likely to develop an inhibitor to factor IX and/or experience allergic reactions. Therefore if you are known to have such a mutation your doctor may monitor you more closely for signs of an allergic reaction particularly when you first start to take BeneFIX.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Because of the risk of allergic reactions with factor IX, your initial administrations of BeneFIX should be performed under medical observation where proper medical care for allergic reactions can be provided.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Even in the absence of factor IX inhibitor, higher doses of BeneFIX may be needed than required for other plasma‑derived factor IX products that you may have taken previously. Therefore, close monitoring of factor IX plasma activity (which measures the ability of your blood to form clots) has to be performed to adjust doses as appropriate. If bleeding is not controlled with the recommended dose, contact your doctor.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from liver or heart disease or if you have recently had surgery, there is an increased risk for blood clotting (coagulation) complications.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A kidney disorder (nephrotic syndrome) has been reported following high doses of plasma‑derived factor IX in haemophilia B patients with factor IX inhibitors and a history of allergic reactions.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sufficient data have not been obtained from clinical studies on the treatment of previously untreated patients (patients who have never received a previous infusion of factor IX), with BeneFIX.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is recommended that evey time you use BeneFIX, you record the name and batch number of the product. You can use one of the peel‑off labels found on the vial to document the batch number in your diary or for reporting any side effects.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Other medicines and BeneFIX</p><p><strong>&nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Pregnancy and breast‑feeding</p><p><strong>&nbsp;</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, you should only take BeneFIX upon specific instructions from your doctor. It is not known whether BeneFIX can cause harm to an unborn baby when given to pregnant women. Your doctor may advise you to stop treatment with BeneFIX if you are breast‑feeding or become pregnant.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>BeneFIX has no influence on the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>BeneFIX contains sodium</strong></p><p>&nbsp;</p><p>After reconstitution, BeneFIX contains 0.2&nbsp;mmol sodium (4.6&nbsp;mg) per vial, that is to say essentially &lsquo;sodium‑free&rsquo;.&nbsp;However, depending on your body weight and your dose of BeneFIX, you could receive multiple vials. This should be taken into consideration if you are on a low salt diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Your doctor will decide the dose of BeneFIX you will receive. This dose and duration will depend upon your individual needs for replacement factor IX therapy and how quickly your body uses up factor IX, which will be checked regularly. You may notice a difference in the dose you receive if you are changing from a plasma‑derived factor IX product to BeneFIX.</p><p>&nbsp;</p><p>Your doctor may decide to change the dose of BeneFIX you receive during your treatment.</p><p><strong>&nbsp;</strong></p><p>Reconstitution and administration</p><p>&nbsp;</p><p>The procedures below are provided as guidelines for the reconstitution and administration of BeneFIX. Patients should follow the specific venipuncture procedures provided by their doctor.</p><p>&nbsp;</p><p>BeneFIX is administered by intravenous (IV) infusion after reconstitution of the powder for injection with the supplied solvent (a sodium chloride (salt) solution) in the pre‑filled syringe.</p><p>&nbsp;</p><p>Always wash your hands prior to performing the following procedures. Aseptic technique (meaning clean and germ free) should be used during the reconstitution procedure.</p><p>&nbsp;</p><p><strong>Reconstitution:</strong></p><p>&nbsp;</p><p>BeneFIX will be administered by intravenous infusion (IV) after reconstitution with sterile solvent for injection.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allow the vial of lyophilised (freeze‑dried) BeneFIX and the pre‑filled syringe to reach room temperature.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the plastic flip‑top cap from the BeneFIX vial to expose the central portion of the rubber stopper.</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_8" o:spid="_x0000_i1032" type="#_x0000_t75"
 style='width:1in;height:1in;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="96" height="96" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /></p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wipe the top of the vial with an alcohol swab provided, or use another antiseptic solution and allow to dry. After cleaning do not touch the rubber stopper with your hand or allow it to touch any surface.</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel back the lid from the clear plastic vial adapter package. Do not remove the adapter from the package.</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the vial on a flat surface. While holding the adapter in the package, place the vial adapter over the vial. Press down firmly on the package until the adapter snaps into place on top of the vial, with the adapter spike penetrating the vial stopper.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_7"
 o:spid="_x0000_i1031" type="#_x0000_t75" alt="Refacto2of8" style='width:1in;
 height:78.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
  o:title="Refacto2of8"/>
</v:shape><![endif]--><img width="96" height="105" alt="Refacto2of8" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png" /></p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lift the package away from the adapter and discard the package.</p><p><em>&nbsp;</em></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_6" o:spid="_x0000_i1030" type="#_x0000_t75" alt="ReFacto5of8"
 style='width:1in;height:86.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
  o:title="ReFacto5of8"/>
</v:shape><![endif]--><img width="96" height="115" alt="ReFacto5of8" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.png" /></p><p>&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attach the plunger rod to the solvent syringe by pushing and turning firmly.</p><p>&nbsp;</p><p>&nbsp;</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Break off the tamper‑resistant plastic tip cap from the solvent syringe by snapping the perforation of the cap. This is done by bending the cap up and down until the perforation is broken. Do not touch the inside of the cap or the syringe tip. The cap may need to be replaced (if not administering reconstituted BeneFIX immediately), so set it aside by placing it on its top.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_5" o:spid="_x0000_i1029" type="#_x0000_t75" alt="ReFacto4of8"
 style='width:76.5pt;height:79.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png"
  o:title="ReFacto4of8"/>
</v:shape><![endif]--><img width="102" height="106" alt="ReFacto4of8" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.png" /></p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the vial on a flat surface. Connect the solvent syringe to the vial adapter by inserting the tip of the syringe into the adapter opening while firmly pushing and turning the syringe clockwise until the connection is secured.</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_4" o:spid="_x0000_i1028" type="#_x0000_t75" alt="newsyringe1"
 style='width:126pt;height:120pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.png"
  o:title="newsyringe1"/>
</v:shape><![endif]--><img width="168" height="160" alt="newsyringe1" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.png" /></p><p>10.&nbsp;&nbsp;&nbsp;&nbsp; Slowly depress the plunger rod to inject all the solvent into the BeneFIX vial</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_3"
 o:spid="_x0000_i1027" type="#_x0000_t75" alt="newsyringe1" style='width:91.5pt;
 height:87.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.png"
  o:title="newsyringe1"/>
</v:shape><![endif]--><img width="122" height="117" alt="newsyringe1" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image012.png" /></p><p>11.&nbsp;&nbsp;&nbsp;&nbsp; With the syringe still connected to the adapter, gently rotate the vial until the powder is dissolved.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:81pt;height:87pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image013.png"
  o:title=""/>
</v:shape><![endif]--><img width="108" height="116" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image014.jpg" /></p><p>12.&nbsp;&nbsp;&nbsp;&nbsp; The final solution should be inspected visually for fine particles before administration. The solution should appear clear and colourless.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Note: If you use more than one vial of BeneFIX per infusion, each vial should be reconstituted as per the previous instructions. The solvent syringe should be removed, leaving the vial adapter in place, and a separate large luer lock (a device that connects the syringe to the vial) syringe may be used to draw back the reconstituted contents of each individual vial.</p><p>&nbsp;</p><p>13.&nbsp;&nbsp;&nbsp;&nbsp; Ensuring that the syringe plunger rod is still fully depressed, invert the vial. Slowly draw back all the solution into the syringe.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:90pt;
 height:88.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image015.png"
  o:title=""/>
</v:shape><![endif]--><img width="120" height="118" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image015.png" /></p><p>14.&nbsp;&nbsp;&nbsp;&nbsp; Detach the syringe from the vial adapter by gently pulling and turning the syringe counter‑clockwise. Discard the vial with the adapter attached.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Note: If the solution is not to be used immediately, the syringe cap should be carefully replaced. Do not touch the syringe tip or the inside of the cap.</p><p>&nbsp;</p><p>BeneFIX should be administered immediately or within 3&nbsp;hours after reconstitution. The reconstituted solution may be stored at room temperature prior to administration.</p><p><strong>&nbsp;</strong></p><p><strong>Administration (Intravenous Injection):</strong></p><p><strong>&nbsp;</strong></p><p>BeneFIX should be administered using the pre‑filled solvent syringe provided or a single sterile disposable plastic luer lock syringe. In addition, the solution should be withdrawn from the vial using the vial adapter.</p><p>&nbsp;</p><p>BeneFIX should be injected intravenously over several minutes. Your doctor may change your recommended infusion rate to make the infusion more comfortable.</p><p>&nbsp;</p><p>There have been reports of clumping (agglutination) of red blood cells in the tube/syringe with the administration of BeneFIX. No side effects have been reported in association with this observation. To minimize the possibility of agglutination, it is important to limit the amount of blood entering the tubing. Blood should not enter the syringe. If clumping of red blood cells in the tubing/syringe is observed, discard all this material (tubing, syringe and BeneFIX solution) and resume administration with a new package.</p><p>&nbsp;</p><p>Because the use of BeneFIX by continuous infusion (drip) has not been evaluated, BeneFIX should not be mixed with infusion solutions or be given in a drip.</p><p>&nbsp;</p><p>Please dispose of all unused solution, empty vials and used needles and syringes in an appropriate container for throwing away waste as it may hurt others if not handled properly.</p><p><strong>&nbsp;</strong></p><p>If you take more BeneFIX than you should</p><p><strong>&nbsp;</strong></p><p>Please contact your doctor immediately if you inject more BeneFIX than your doctor recommends.</p><p>&nbsp;</p><p>If you stop taking BeneFIX</p><p><strong>&nbsp;</strong></p><p>Do not stop taking BeneFIX without consulting your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Hypersensitivity/allergic reactions</p><p><strong>&nbsp;</strong></p><p>Allergic-type hypersensitivity reactions are possible with BeneFIX. Such reactions may include swelling of the face or throat, burning and stinging at the infusion site, chills, flushing, itching, headache, hives, low blood pressure, lethargy, nausea, restlessness, fast heart rate, tightness of the chest, tingling, vomiting, wheezing). In some cases, these reactions have progressed to severe anaphylaxis. Allergic reactions may occur together with the development of factor IX inhibitor (see also &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>These reactions are potentially life‑threatening. If allergic/anaphylactic reactions occur, <strong>stop the infusion immediately and contact your doctor or seek emergency medical care immediately.</strong> The treatment required depends on the nature and severity of side‑effects (see also &ldquo;Warnings and precautions&rdquo;).</p><p><strong>&nbsp;</strong></p><p>Inhibitor development</p><p>&nbsp;</p><p>Patients with haemophilia B may develop neutralising antibodies (inhibitors) to factor IX. If such inhibitors occur, a sign may be an increase in the amount of BeneFIX typically required to treat a bleed and or continued bleeding after treatment. In such cases, it is recommended that a specialised haemophilia centre be contacted. Your doctor may want to monitor you for inhibitor development (see &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>A kidney disorder has been reported following high doses of plasma‑derived factor IX to induce immune tolerance in haemophilia B patients with factor IX inhibitors and a history of allergic reactions (see also &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>Thrombotic events</p><p><u>&nbsp;</u></p><p>BeneFIX may increase the risk of thrombosis (abnormal blood clots) in your body if you have risk factors for developing blood clots, including an indwelling venous catheter. There have been reports of severe blood clotting events, including life‑threatening blood clots in critically ill babies, while receiving continuous‑infusion BeneFIX through a central venous catheter. Cases of peripheral thrombophlebitis (pain and redness of the veins) and deep venous thrombosis (blood clots in the extremities) have also been reported; in most of these cases, BeneFIX was administered via continuous infusion, which is not an approved method of administration.</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp; Cough</p><p>&middot;&nbsp;&nbsp;&nbsp; Fever</p><p>&nbsp;</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 people)</p><ul><li>Hypersensitivity/allergic reactions</li><li>Dizziness, altered taste</li><li>Phlebitis (pain and redness of veins), flushing</li><li>Vomiting, nausea</li><li>Rash, hives</li><li>Chest discomfort (including chest pain)</li><li>Infusion-site reaction (including itching and redness at the infusion site), infusion-site pain and discomfort</li></ul><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Development of neutralising antibodies (inhibitors)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion site cellulitis (pain and redness of the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness, shaking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision impairment (including blurred vision, appearance of spots/lights)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart rate, low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal infarct (interruption to the blood supply to the kidney)</p><p>&nbsp;</p><p><strong>Side effects with unknown frequency </strong>(frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombotic events (abnormal blood clots)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of response to treatment (failure to stop or prevent bleeding episodes)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects:</strong></p><p>&nbsp;</p><p>Saudi Arabia:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>&middot;&nbsp;&nbsp; &nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; Fax: +966 11 205 7662</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website:https://ade.sfda.gov.sa/&nbsp;&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use Benefix after the expiry date which is stated on the outer box and vial label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>BeneFIX must be stored continuously in a refrigerator at a temperature of 2&deg;C to 8&deg;C and must be used by the expiry date on the label.</p><p>&nbsp;</p><p>Do not freeze in order to prevent damage to the pre‑filled syringe.</p><p>&nbsp;</p><p>Use the reconstituted solution immediately or within 3&nbsp;hours.</p><p>&nbsp;</p><p>Do not use this medicine if you notice the solution is not clear or colourless.</p><p>&nbsp;</p><p>Use only the pre‑filled syringe provided in the box for reconstitution. Other sterile disposable syringes may be used for administration.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is nonacog alfa (recombinant coagulation factor IX). Each vial of BeneFIX contains nominally 250, 500, 1000, or 2000&nbsp;IU of nonacog alfa.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sucrose, glycine, L‑histidine, polysorbate 80. A solvent (0.234% sodium chloride solution) is also supplied for reconstitution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After reconstitution with the supplied solvent (0.234% sodium chloride solution), each vial contains 50, 100, 200 or 400 IU/ml (see Table 1).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Table 1. Strength of BeneFIX per ml prepared solution</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Amount of BeneFIX per Vial </strong></p></td><td style="vertical-align:top"><p><strong>Amount of BeneFIX per 1&nbsp;ml of prepared solution for injection</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>250&nbsp;IU</p></td><td style="vertical-align:top"><p>50&nbsp;IU</p></td></tr><tr><td style="vertical-align:top"><p>500&nbsp;IU</p></td><td style="vertical-align:top"><p>100&nbsp;IU</p></td></tr><tr><td style="vertical-align:top"><p>1000&nbsp;IU</p></td><td style="vertical-align:top"><p>200&nbsp;IU</p></td></tr><tr><td style="vertical-align:top"><p>2000&nbsp;IU</p></td><td style="vertical-align:top"><p>400&nbsp;IU</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BeneFIX is provided as a powder for injection in a glass vial and a solvent provided in pre filled syringe. 

The contents of the pack are:
	
•	one vial of BeneFIX 250, 500, 1000 or 2000 IU powder
•	one pre filled syringe of solvent, 5 ml sterile 0.234% sodium chloride solution for injection for reconstitution, with one plunger rod
•	one sterile vial adapter reconstitution device
•	one sterile infusion set
•	two alcohol swabs
•	one plaster
•	one gauze pad


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Wyeth Farma S.A.</p><p>Autovia del Norte A-1, Km. 23. Desvio Algete, Km. 1, 28700 S. Sebastian de los Reyes, Madrid</p><p>Spain</p><p>&nbsp;</p><p>Manufacturing, PACKAGING &amp; RELEASED BY:</p><p>&nbsp;</p><p>Wyeth Farma S.A.</p><p>Autovia del Norte A-1, Km. 23. Desvio Algete, Km. 1, 28700 S. Sebastian de los Reyes, Madrid</p><p>Spain</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                EU: November 2020

USPI: June 2020

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>بينيفيكس هو منتج عبارة عن عامل التخثر التاسع قابل للحقن يُنتج بواسطة تكنولوجيا الحمض النووي (DNA) المأشوب. المكون الفعال لبينيفيكس هو ألفا نوناكوج. يكون لدى الأشخاص الذين يولدون بداء الهيموفيليا ب (مرض كريسماس) نقص في العامل التاسع الذي يقوم بالتحكم في النزيف. يعمل بينيفيكس عن طريق استبدال العامل التاسع في المرضى المصابين بداء الهيموفيليا ب لتمكين الدم من التجلط</p><p>يُستخدم بينيفيكس في علاج والوقاية من النزيف في المرضى المصابين بـ الهيموفيليا ب (نقص العامل التاسع الخلقي) في جميع الفئات العمرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استعمال بينيفيكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه ألفا نوناكوج أو أي مكون آخر من مكونات هذا الدواء (المُدرجة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه بروتينات الهامستر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال بينيفيكس</strong></p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث إلى طبيبك أو الصيدلي قبل استخدام بينيفيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راجع طبيبك على الفور إذا لم يتوقف نزيفك على النحو المتوقع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية واردة الحدوث. قد يحتوي المنتج على كميات صغيرة من بروتينات الهامستر (انظر قسم &quot;لا تتناول بينيفيكس في الحالات التالية&quot;). حدثت حالات من التفاعلات التأقية (تفاعلات حساسية شديدة) تشكل خطورة محتملة على الحياة مع المنتجات التي تحتوي على العامل التاسع، بما فيها بينيفيكس. تشمل العلامات المبكرة لتفاعلات الحساسية صعوبة التنفس وضيق التنفس وتورمًا وشرى وحكة وارتيكاريا معممة وضيق منطقة الصدر وأزيز وانخفاض ضغط الدم و تغيم الرؤية وصدمة تأقية (تفاعل حساسية شديد قد يسبب صعوبة في البلع و/أو التنفس، احمرار أو تورم الوجه و/أو الأيدي).</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة حدوث تفاعلات حساسية أو تفاعلات تأقية، <strong>أوقف دخول السائل الى الوريد ( الحقن الوريدي البطيء) فورًا واتصل بالطبيب أو اطلب رعاية طبية طارئة على الفور</strong>. وفي حالة حدوث تفاعلات الحساسية الشديدة، يجب مراعاة العلاجات البديلة المتوفرة</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُعتبر الأجسام المضادة المعادلة للنشاط (المثبطات) إحدى الحوادث غير الشائعة عند المرضى الذين تلقوا علاجًا سابقًا بإحدى المنتجات التي تحتوي على العامل التاسع. ومع ذلك، كما هو الحال مع جميع المنتجات التي تحتوي على العامل التاسع، ينبغي أن تتم مراقبتك بدقة لرصد تكوّن مثبطات العامل التاسع أثناء علاجك ببينيفيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أظهرت الأبحاث وجود علاقة بين ظهور مثبطات العامل التاسع وتفاعلات الحساسية. لذا، إذا عانيت من تفاعلات حساسية مثل تلك التي تم وصفها أعلاه، يجب أن تخضع للاختبار لتبين وجود أحد المثبطات من عدمه. تجدر الملاحظة بأن المرضى الذين يعانون من وجود مثبطات العامل التاسع قد يكونوا معرضين لزيادة خطر الإصابة بالتأق أثناء العلاج ببينيفيكس في المستقبل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتحكم جين العامل التاسع في إنتاج العامل التاسع داخل الجسم. قد يكون المرضى الذين يعانون من بعض الطفرات في جين العامل التاسع لديهم، مثل حذف المادة الجينية الرئيسية، أكثر عرضة لتكوين مثبط للعامل التاسع و/أو التعرض لتفاعلات حساسية. لذا، إذا كانت إصابتك بمثل هذه الطفرة أمرًا معروفًا، فقد يقوم طبيبك بمراقبتك عن كثب للكشف عن علامات تفاعلات الحساسية خاصةً عند بدء استخدام بينيفيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بسبب خطر الإصابة بتفاعلات الحساسية عند استعمال المنتجات التي تحتوي على العامل التاسع، ينبغي تلقي بينيفيكس لأول مرة تحت إشرافٍ طبي حيث يمكن توفير الرعاية الطبية الملائمة عند حدوث اي من تفاعلات الحساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حتى في غياب مثبطات العامل التاسع، فقد يحتاج الأمر إلى تلقي جرعات أعلى من بينيفيكس مُقارنة بالتي تتطلبها المنتجات الأخرى التي تحتوي على العامل التاسع المشتق من البلازما والتي قد تكون تناولتها في السابق. لذا، يجب إجراء مراقبة دقيقة لنشاط العامل التاسع في البلازما (والتي تقيس قدرة الدم على تكوين جلطات) لضبط الجرعات كما يجب. إذا لم تتم السيطرة على النزيف باستخدام الجرعة الموصى بها، فاتصل بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض بالكبد أو القلب أو خضعت حديثًا للجراحة، فهناك خطر متزايد للإصابة بمضاعفات تجلط (تخثر) الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن حدوث اضطرابات بالكلى (المتلازمة الكلوية) بعد تناول جرعات عالية من العامل التاسع المشتق من البلازما في المرضى المصابين بالهيموفيليا ب ممن ظهرت لديهم مثبطات العامل التاسع ولديهم تاريخ للإصابة بتفاعلات الحساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يتم الحصول على بيانات وافية من الدراسات السريرية فيما يتعلق بعلاج المرضى الذين لم يتم علاجهم من قبل (المرضى الذين لم يتلقوا علاج بالحقن الوريدية البطيئة لمنتج يحتوي على العامل التاسع إطلاقًا من قبل)، عند استعمال&nbsp; بينيفيكس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يوصى بأن تقوم في كل مرة تستخدم فيها بينيفيكس بتسجيل اسم ورقم دفعة الانتاج المنتج.</p><p dir="RTL">يمكنك استخدام أحد الملصقات القابلة للنزع الموجودة على القارورة لتوثيق رقم الدفعة في مفكرتك اليومية أو للإبلاغ عن أي آثار جانبية.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL"><em>&nbsp;</em></p><p><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملاً أو تخططين للحمل، ينبغي تناول بينيفيكس فقط بناءً على التعليمات المخصصة التي يقوم طبيبك بإعطائها إليكِ. لا يُعرف إذا ما كان يمكن لبينيفيكس أن يسبب ضررًا للأجنة عند إعطائه للنساء الحوامل. قد ينصحك طبيبكِ بإيقاف العلاج ببينيفيكس إذا كنتِ ترضعين طفلك رضاعة طبيعية أو إذا أصبحتِ حاملًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p><strong>تأثير بينيفيكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يؤثر بينيفيكس على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات بينيفيكس</strong></p><p dir="RTL"><strong>يحتوي بينيفيكس على الصوديوم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">بعد التحضير، يحتوي بينيفيكس على ٠,٢ مليمول صوديوم (٤,٦ ملجم) لكل زجاجة، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي. ومع ذلك يمكنك تلقي عدة زجاجات، بناءً على وزن جسمك والجرعة المحددة لك من بينيفيكس. ينبغي أن يؤخذ ذلك في الاعتبار إذا كنت تتبع نظامًا غذائيًا قليل الملح.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ينبغي عليك دائمًا تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p>&nbsp;</p><p>سوف يقرر طبيبك مقدار جرعة بينيفيكس التي ستتلقاها. ستعتمد هذه الجرعة ومدتها على احتياجاتك الفردية للعلاج البديل للعامل التاسع وعلى سرعة جسمك في استهلاك العامل التاسع، والذي سيتم فحصه بانتظام. قد تشعر بوجود فرق في الجرعة التي تتلقاها عند التغيير من منتج يحتوي على العامل التاسع المشتق من البلازما إلى بينيفيكس.</p><p>&nbsp;</p><p>قد يقرر طبيبك تغيير جرعة بينيفيكس التي تتلقاها أثناء فترة علاجك.</p><p><strong>&nbsp;</strong></p><p><u>التحضير وطريقة الاستعمال </u></p><p>&nbsp;</p><p>تُقدَّم الإجراءات المذكورة أدناه كتوجيهات لتحضير واستعمال بينيفيكس. ينبغي على المرضى اتباع إجراءات ثقب الوريد المحددة التي أبلغهم بها الطبيب.</p><p>&nbsp;</p><p>يتم استعمال بينيفيكس عن طريق (IV) بعد تحضير المسحوق للحقن باستخدام المذيب المرفق (محلول&nbsp; كلوريد الصوديوم (ملحي)) في المحقنة مسبقة التعبئة.</p><p>&nbsp;</p><p>اغسل يديك دائمًا قبل تنفيذ الإجراءات التالية. ينبغي استخدام اساليب وتقنيات معقمة (بمعنى أن يكون نظيفًا وخاليًا من الجراثيم) أثناء عملية التحضير.</p><p>&nbsp;</p><p><strong>التحضير:</strong></p><p>&nbsp;</p><p>سيتم استعمال بينيفيكس عن طريق الحقن الوريدي البطيء (IV) بعد تحضيره باستخدام محلول معقم للحقن.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اترك زجاجة بينيفيكس المُجفد (مجففة بالتجميد) والمحقنة مسبقة التعبئة حتى تصل إلى درجة حرارة الغرفة.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بنزع الغطاء البلاستيكي الذي يُفتح بنقره لأعلى من على زجاجة بينيفيكس ليظهر الجزء الأوسط من السدادة المطاطية.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بمسح أعلى زجاجة باستخدام مسحة الكحول المرفقة، أو استخدم أي محلول تعقيم آخر واتركها لتجف. وبعد التنظيف لا تلمس السدادة المطاطية بيديك ولا تسمح لها بأن تلمس أي سطح.</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بنزع الغطاء عن عبوة مهيء الزجاجة البلاستيكية الشفافة. لا تقم بإخراج الاداة المهيئة للمحقنة من العبوة.</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع القنينة على سطحٍ مستوٍ. أثناء حمل عبوة مهيء الزجاجة ، ضع الاداة المهيئة على قمة ا الزجاجة. اضغط على العبوة لأسفل بقوة حتى يستقر مهيء الزجاجة في مكانه أعلى الزجاجة مع سماع صوت طقطقة، بحيث يخترق سن المهيء سدادة الزجاج.</p><p>&nbsp;</p><p>&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإبعاد العبوة من على مهيء الزجاجة ثم تخلص من العبوة.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثبت مقبض الكبس على محقنة المذيب عن طريق ضغطها وإدارتها بقوة.</p><p>&nbsp;</p><p>&nbsp;</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بكسر الغطاء العلوي البلاستيكي المقاوم للعبث من على محقنة المذيب عن طريق كسر الغطاء عند الموضع المخصص لذلك. يتم فعل هذا عن طريق ثني الغطاء لأعلى ولأسفل حتى يتم الكسر عند الموضع المخصص لذلك. لا تلمس الجزء الداخلي من الغطاء أو طرف الإبرة. قد تحتاج إلى تغيير الغطاء (إذا لم تستعمل بينيفيكس المُحضَّر على الفور)، لذا ضعه جانبًا بوضعه على الجهة العليا.</p><p>&nbsp;</p><p>&nbsp;</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع الزجاجة على سطحٍ مستوٍ. قم بتوصيل محقنة المذيب مهيء الزجاجة عن طريق إدخال طرف المحقنة في فتحة مهيء الزجاجة مع الضغط بقوة وإدارة المحقنة في اتجاه عقارب الساعة حتى يتم التوصيل بإحكام.</p><p>&nbsp;</p><p>&nbsp;</p><p>10.&nbsp;&nbsp;&nbsp;&nbsp; اضغط على مقبض الكبس ببطء لحقن المحلول بأكمله داخل زجاجة بينيفيكس.</p><p>&nbsp;</p><p>11.&nbsp;&nbsp;&nbsp;&nbsp; والمحقنة لا تزال مرتبطة مهيء الزجاجة، أدِر الزجاجة برفق إلى أن يذوب المسحوق.</p><p>&nbsp;</p><p>&nbsp;</p><p>12.&nbsp;&nbsp;&nbsp;&nbsp; ينبغي فحص المحلول النهائي بصريًا للتحقق من وجود جسيمات دقيقة قبل الاستعمال. يجب أن يظهر المحلول صافي وشفافًا.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ملاحظة: إذا استخدمت أكثر من زجاجة واحدة من عبوات بينيفيكس للحقن الوريدي البطيء الواحد ، فينبغي أن تُحضَّر كل واحدة منها وفقًا للتعليمات السابقة. يجب نزع محقنة المذيب، مع ترك مهيء الزجاجة في مكانه، ويمكن استخدام محقنة منفصلة ذات قفل لور (جهاز يصل المحقنة بالقنينة) لسحب المحتوى المُحضَّر من كل واحدة من القنينات.</p><p>&nbsp;</p><p>13.&nbsp;&nbsp;&nbsp;&nbsp; بعد التأكد من أن مقبض المحقنة الكابس لا يزال مضغوطًا تمامًا، اقلب الزجاجة اسحب المحلول بأكمله ببطء إلى المحقنة.</p><p>&nbsp;</p><p>&nbsp;</p><p>14.&nbsp;&nbsp;&nbsp;&nbsp; أزِل المحقنة من مهيء الزجاجة عن طريق سحب المحقنة برفق وإدارتها عكس اتجاه عقارب الساعة. قم بالتخلص من الزجاجة والمهيء المرتبط بها.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ملاحظة: إذا لم يتم استخدام المحلول على الفور، ينبغي إعادة غطاء المحقنة إلى مكانه بحذر. لا تلمس طرف الإبرة أو الجزء الداخلي من الغطاء.</p><p>&nbsp;</p><p>ينبغي استعمال بينيفيكس في الحال أو خلال 3 ساعات بعد تحضيره. يمكن تخزين المحلول الذي تم تحضيره في درجة حرارة الغرفة قبل الاستعمال.</p><p>&nbsp;</p><p><strong>الاستعمال (الحقن في الوريد):</strong></p><p>&nbsp;</p><p>ينبغي استعمال بينيفيكس باستخدام المحاقن مسبقة التعبئة بالمذيب المرفقة أو محقنة واحدة معقمة معدة للاستخدام مرة واحدة مزودة بقفل لور البلاستيكي. بالإضافة إلى ذلك، ينبغي سحب المحلول من الزجاجة باستخدام مهيء الزجاجة</p><p>ينبغي حقن بينيفيكس عن طريق الوريد لعدة دقائق. قد يغير طبيبك من معدل الحقن المُوصى به لجعل عملية الحقن أكثر راحة.</p><p>&nbsp;</p><p>تم الإبلاغ عن حدوث تكتل (التصاق) خلايا الدم الحمراء في الأنبوب/المحقنة عند استعمال بينيفيكس. لم يتم الإبلاغ عن أي آثار جانبية مصاحبة لهذه الملاحظة. لتقليل إمكانية حدوث تلاصق، فمن الضروري الحد من كمية الدم التي تدخل إلى الأنبوب. ينبغي ألّا يدخل الدم إلى المحقنة. إذا لوحظ تكتل خلايا الدم الحمراء في الأنبوب/المحقنة، فقم بالتخلص من جميع هذه الأدوات (الأنبوب والمحقنة ومحلول بينيفيكس) ثم قم بإعطاء الجرعة المحددة باستخدام عبوة جديدة.</p><p>&nbsp;</p><p>نظرًا لعدم تقييم استخدام بينيفيكس عن طريق الحقن الوريدي المستمر (التنقيط)، ينبغي عدم خلط بينيفيكس بمحاليل الحقن الوريدي أو إعطاؤه بالتنقيط.</p><p>&nbsp;</p><p>يرجى التخلص من جميع المحاليل غير المستخدمة و الزجاجات الفارغة والإبر والمحاقن المستعملة في حاوية ملائمة مخصصة للتخلص من المخلفات حيث أنها يمكن أن تؤذي الآخرين إن لم يتم التخلص منها بصورة سليمة.</p><p><strong>&nbsp;</strong></p><p><strong>في حالة تناولك جرعة من بينيفيكس أكبر مما ينبغي</strong></p><p>&nbsp;</p><p>يرجى الاتصال بطبيبك في الحال إذا قمت بحقن كمية من بينيفيكس أكثر مما أوصى بها طبيبك.</p><p>&nbsp;</p><p><strong>في حالة التوقف عن تناول بينيفيكس</strong></p><p>&nbsp;</p><p>لا تتوقف عن استعمال بينيفيكس دون استشارة طبيبك.</p><p>&nbsp;</p><p>إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p>&nbsp;</p><p><strong>تفاعلات فرط التحسس/الحساسية </strong></p><p><strong>&nbsp;</strong></p><p>من المحتمل حدوث تفاعلات فرط التحسس مع بينفيكس. قد تتضمن هذه التفاعلات تورم الوجه أو الحلق، الشعور بالحرقان والوخز في موضع التسريب، القشعريرة، الاحمرار، الحكة، الصداع، الشرى، ضغط الدم المنخفض، الخمول، الغثيان، التململ، سرعة معدل نبضات القلب، ضيق الصدر، التنميل، القيء، الأزيز. في بعض الحالات، تطورت هذه التفاعلات إلى صدمة تأقية شديدة. قد تحدث تفاعلات الحساسية مع تكوّن ثبطات العامل التاسع (انظر أيضًا القسم &quot;تحذيرات واحتياطات&quot;).</p><p>&nbsp;</p><p>يحتمل أن تكون هذه التفاعلات مهددة للحياة. في حالة حدوث تفاعلات حساسية/تفاعلات تأقية، <strong>أوقف</strong><strong> </strong>الحقن الوريدي البطيء <strong>فورًا</strong><strong> </strong><strong>واتصل</strong><strong> </strong><strong>بطبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>اطلب</strong><strong> </strong><strong>رعاية</strong><strong> </strong><strong>طبية</strong><strong> </strong><strong>طارئة</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong>.</strong> يعتمد العلاج المستلزم على طبيعة وشدة الآثار الجانبية (انظر أيضًا القسم &quot;تحذيرات واحتياطات&quot;).</p><p><strong>&nbsp;</strong></p><p><strong>تكوّن</strong><strong> </strong><strong>المثبطات</strong></p><p>&nbsp;</p><p>قد تنشأ لدى المرضى المصابين بالهيموفيليا ب أجسام مضادة معادلة (مثبطات) للعامل التاسع. إذا ظهرت مثل هذه المثبطات، فقد تتمثل العلامة على ظهورها في زيادة كمية بينيفيكس اللازمة عادةً لعلاج نزيف و/أو استمرار النزيف بعد العلاج. في هذه الحالات، يُوصى بالاتصال بمركز متخصص لعلاج الهيموفيليا. قد يريد طبيبك مراقبتك لفحص تكوّن المثبط (انظر القسم &quot;تحذيرات واحتياطات&quot;).</p><p>&nbsp;</p><p>تم الإبلاغ عن اضطراب الكلى بعد تناول جرعات عالية من العامل التاسع المشتق من البلازما لتحفيز التحمل المناعي في المرضى المصابين بالهيموفيليا ب ممن ظهرت لديهم مثبطات العامل التاسع ولديهم تاريخ للإصابة بتفاعلات الحساسية. (انظر أيضًا القسم &quot;تحذيرات واحتياطات&quot;).</p><p>&nbsp;</p><p><strong>الأحداث الخثارية</strong></p><p><u>&nbsp;</u></p><p>قد يزيد بينيفيكس من خطر التخثر (جلطات الدم غير الطبيعية) في جسمك إذا كانت لديك عوامل خطر للإصابة بجلطات الدم، بما في ذلك القسطرة الوريدية المستقرة. تم الإبلاغ عن وقوع حالات تجلط للدم شديدة ، بما في ذلك جلطات الدم المهددة للحياة للاطفال المصابين ، أثناء تناول بينيفيكس عن طريق&nbsp; الحقن الوريدي المستمر عبر&nbsp; القسطرة الوريدية المركزية. تم الإبلاغ أيضًا عن حالات مصابة بالتهاب الوريد الخثاري المحيطي (ألم واحمرار الأوردة) والتخثرات الوريدية العميقة (تجلط الدم في الأطراف)؛ في معظم هذه الحالات، تم استعمال بينيفيكس عن طريق الحقن الوريدي المستمر، والذي لا يعد أسلوبًا معتمدًا للاستعمال.</p><p>&nbsp;</p><p><strong>الآثار الجانبية الشائعة جدًا </strong>(قد تؤثر على أكثر من شخص واحد من بين كل 10 أشخاص)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p>&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;الحمى</p><p>&nbsp;</p><p><strong>الآثار الجانبية الشائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من بين كل 10 أشخاص)</p><p>&middot;&nbsp;&nbsp;&nbsp; تفاعلات فرط التحسس/الحساسية</p><p>&middot;&nbsp;&nbsp;&nbsp; الدوار، تغير في الذوق</p><p>&middot;&nbsp;&nbsp;&nbsp; التهاب الوريد (ألم في الأوردة واحمرارها)، الاحمرار</p><p>&middot;&nbsp;&nbsp;&nbsp; القيء، الغثيان</p><p>&middot;&nbsp;&nbsp;&nbsp; الطفح الجلدي، الشرى</p><p>&middot;&nbsp;&nbsp;&nbsp; انزعاج في الصدر (بما في ذلك ألم الصدر)</p><p>&middot;&nbsp;&nbsp;&nbsp; تفاعلات موضع التسريب (بما في ذلك الشعور بالحكة في موضع التسريب واحمراره)، الشعور بألم وانزعاج في موضع التسريب</p><p>&nbsp;</p><p><strong>الآثار الجانبية غير الشائعة </strong>(قد تؤثر على شخص واحد من بين كل 100 شخص)&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; تكوّن أجسام مضادة معادلة (مثبطات)</p><p>&middot;&nbsp;&nbsp; التهاب الهلل (التهاب الأنسجة الضامة) في موضع التسريب (ألم واحمرار الجلد)</p><p>&middot;&nbsp;&nbsp; النعاس، الرعشة</p><p>&middot;&nbsp;&nbsp; خلل في الرؤية (بما في ذلك تغيم الرؤية، ظهور بقع/أضواء)</p><p>&middot;&nbsp;&nbsp; سرعة معدل نبضات القلب، ضغط الدم المنخفض</p><p>&middot;&nbsp;&nbsp; احتشاء في الكلى (انقطاع إمداد الدم إلى الكلى)</p><p>&nbsp;</p><p><strong>الآثار الجانبية ذات معدل التكرار غير المعروف</strong> (لا يمكن تقدير معدل التكرار من البيانات المتوفرة)</p><p>&middot;&nbsp;&nbsp;&nbsp; تفاعل تأقي</p><p>&middot;&nbsp;&nbsp;&nbsp; أحداث خثارية (جلطات دم غير طبيعية)</p><p>&middot;&nbsp;&nbsp;&nbsp; ضعف الاستجابة للعلاج (فشل إيقاف أو منع حالات النزف)</p><p><strong>&nbsp;</strong></p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا ظهرت عليك أي آثار جانبية، فأخبر طبيبك أو الصيدلي. يشتمل هذا على أي آثار جانبية محتملة وغير مدرجة في هذه النشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">للإبلاغ عن الآثار الجانبية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong><strong> (</strong><strong>NPC</strong><strong>)</strong></p><ul><li dir="RTL">&nbsp;&nbsp;</li><li dir="RTL">مركز الاتصال: ١٩٩٩٩</li><li dir="RTL">الفاكس: 7662 205 11 966+</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج الأخرى:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p>لا تستخدم بينيفيكس بعد انتهاء فترة الصلاحية المُبينة على العبوة الخارجية والملصق الموجود على العبوة يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p>&nbsp;</p><p>يجب تخزين بينيفيكس في الثلاجة فى&nbsp; &nbsp;درجة حرارة تتراوح ما بين 2 درجة مئوية الى 8 درجة مئوية ويجب أن يُستخدم قبل مرور تاريخ الصلاحية المكتوب على الملصق.</p><p>&nbsp;</p><p>لا تجمده حتى تحول دون تحطيم المحقنة مسبقة التعبئة بالمذيب.</p><p>&nbsp;</p><p>استخدم المحلول المعاد تحضيره في الحال أو خلال 3 ساعات.</p><p>&nbsp;</p><p>لا تستخدم هذا الدواء إذا لاحظت أن المحلول ليس صافيا أو شفافًا.</p><p>&nbsp;</p><p>استخدم المحقنة مسبقة التعبئة الموجودة في الصندوق فقط للتحضير. يمكن استخدام إحدى المحاقن الأخرى المعقمة والمُعدة للاستخدام مرة واحدة عند الاستعمال.</p><p>&nbsp;</p><p>يجب عدم التخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن الطريقة المثلى للتخلص من أي أدوية لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>المادة الفعالة هي ألفا نوناكوج (عامل التخثر التاسع المأشوب). تحتوي كل زجاجة</strong><strong> </strong><strong>من بينيفيكس على مسحوق بتركيز يبلغ 250 أو 500 أو 1000 أو 2000 &nbsp;وحدة دولية من ألفا نوناكوج.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي سكروز، جليسين، ل-هيستيدين، بوليسوربات 80. يتم توفير أيضًا المذيب (0.234% محلول كلوريد الصوديوم) لتحضيره.</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>بعد إعادة التحضير باستخدام المذيب المرفق (محلول كلوريد الصوديوم بتركيز 0.234%)، تحتوي كل زجاجة على 50 أو 100 أو 200 أو 400 وحدة دولية/مل (انظر الجدول 1).</strong></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجدول 1. تركيز محلول بينيفيكس المحضر لكل مل.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>كمية بينيفيكس في كل قنينة </strong></p></td><td style="vertical-align:top"><p><strong>كمية بينيفيكس لكل 1 مل من المحلول المجهز للحقن</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>250&nbsp;وحدة دولية</p></td><td style="vertical-align:top"><p>50&nbsp;وحدة دولية</p></td></tr><tr><td style="vertical-align:top"><p>500&nbsp;وحدة دولية</p></td><td style="vertical-align:top"><p>100&nbsp;وحدة دولية</p></td></tr><tr><td style="vertical-align:top"><p>1000&nbsp;وحدة دولية</p></td><td style="vertical-align:top"><p>200&nbsp;وحدة دولية</p></td></tr><tr><td style="vertical-align:top"><p>2000&nbsp;وحدة دولية</p></td><td style="vertical-align:top"><p>400&nbsp;وحدة دولية</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر بينيفيكس في شكل مسحوق للحقن في عبوة زجاجية مع مذيب متوفر في محقنة مسبقة التعبئة. محتويات العبوة هي: &middot; عبوة زجاجية واحدة من مسحوق بينيفيكس 250 أو 500 أو 1000 أو 2000 وحدة دولية &bull; محقنة واحدة مسبقة التعبئة من المذيب، 5 مل من محلول كلوريد الصوديوم المعقم بتركيز 0.234% للحقن للتحضير، مع مقبض كابس واحد &bull; جهاز مهيء العبوة الزجاجية واحد معقم للتحضير &bull; مجموعة واحدة معقمة مستخدمة في التسريب &bull; عدد 2 مسحة كحول &bull; لصقة واحدة &bull; ضمادة واحدة من الشاش</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التسويق</strong></p><p>&nbsp;</p><p>Wyeth Farma S.A.</p><p>Autovia del Norte. A-1, Km. 23. Desvio Algete, Km. 1, 28700 San. Sebastian de los Reyes, Madrid</p><p>Spain (إسبانيا)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>الشركة المصنعة والمسؤولة عن التعبئة: </strong></p><p>&nbsp;</p><p>Wyeth Farma S.A.</p><p>Autovia del Norte. A-1, Km. 23. Desvio Algete, Km. 1, 28700 San. Sebastian de los Reyes, Madrid</p><p>Spain (إسبانيا)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            الاتحاد الأوروبي: نوفمبر/تشرين الثاني ٢٠٢٠

 USPI: يونيو/حزيران ٢٠٢٠

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BeneFIX 250 IU powder and solvent for solution for injection
BeneFIX 500 IU powder and solvent for solution for injection
BeneFIX 1000 IU powder and solvent for solution for injection
BeneFIX 2000 IU powder and solvent for solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BeneFIX 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU nonacog alfa (recombinant coagulation factor IX). After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 50 IU nonacog alfa.

BeneFIX 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU nonacog alfa (recombinant coagulation factor IX). After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 100 IU nonacog alfa.

BeneFIX 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU nonacog alfa (recombinant coagulation factor IX). After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 200 IU nonacog alfa.

BeneFIX 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU nonacog alfa (recombinant coagulation factor IX). After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 400 IU nonacog alfa.

 
The potency (IU) is determined using the European Pharmacopoeia one-stage clotting assay. The specific activity of BeneFIX is not less than 200 IU/mg protein.

BeneFIX contains recombinant coagulation factor IX, (INN = nonacog alfa). Nonacog alfa is a purified protein that has 415 amino acids in a single chain. It has a primary amino acid sequence that is comparable to the Ala148 allelic form of plasma-derived factor IX, and some post-translational modifications of the recombinant molecule are different from those of the plasma-derived molecule. Recombinant coagulation factor IX is a glycoprotein that is secreted by genetically engineered mammalian cells derived from a Chinese hamster ovary (CHO) cell line. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BeneFIX 250 IU, 500 IU, 1000 IU , 2000 IU powder and solvent for solution for injection
Powder and solvent for solution for injection
White/almost white powder and clear and colourless solvent.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor&nbsp;IX deficiency).</p><p>&nbsp;</p><p>BeneFIX can be used for all age groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be under the supervision of a physician experienced in the treatment of haemophilia.</p><p>&nbsp;</p><p><u>Treatment monitoring</u></p><p>During the course of treatment, appropriate determination of factor IX levels is advised to guide the dose to be administered and the frequency of repeated infusions. Individual patients may vary in their response to factor IX, demonstrating different half-lives and recoveries. Dose based on bodyweight may require adjustment in underweight or overweight patients. In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor IX activity) is indispensable.</p><p>&nbsp;</p><p>When using an in vitro thromboplastin time (aPTT)-based one stage clotting assay for determining factor IX activity in patients&rsquo; blood samples, plasma factor IX activity results can be significantly affected by both the type of aPTT reagent and the reference standard used in the assay. This is of importance particularly when changing the laboratory and/or reagents used in the assay.</p><p>&nbsp;</p><p><u>Posology</u></p><p>Dose and duration of the substitution therapy depend on the severity of the factor IX deficiency, on the location and extent of bleeding, and on the patient&#39;s clinical condition.</p><p>&nbsp;</p><p>The number of units of factor IX administered is expressed in International Units (IU), which is related to the current WHO standard for factor IX products. Factor IX activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an international standard for factor IX in plasma).</p><p>&nbsp;</p><p>One International Unit (IU) of factor IX activity is equivalent to that quantity of factor IX in one mL of normal human plasma.</p><p>&nbsp;</p><p><em><u>On demand treatment</u></em></p><p>The calculation of the required dose of BeneFIX can be based on the finding that one unit of factor IX activity per kg body weight is expected to increase the circulating level of factor&nbsp;IX, an average of 0.8&nbsp;IU/dL (range from 0.4 to 1.4&nbsp;IU/dL) in patients &sup3;&nbsp;12&nbsp;years (further information in section&nbsp;5.2).</p><p>&nbsp;</p><p>The required dose is determined using the following formula:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Number of factor IX IU required</p></td><td style="vertical-align:top"><p>=</p></td><td style="vertical-align:top"><p>body weight (in kg)</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top"><p>desired factor IX increase (%) or (IU/dL)</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top"><p>reciprocal of observed recovery</p></td></tr></tbody></table><p>&nbsp;</p><p>Example: For a recovery of 0.8&nbsp;IU/dL, the formula reads:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Number of factor IX IU required</p></td><td style="vertical-align:top"><p>=</p></td><td style="vertical-align:top"><p>body weight (in kg)</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top"><p>desired factor IX increase (%) or (IU/dL)</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top"><p>1.3&nbsp;IU/kg</p></td></tr></tbody></table><p>&nbsp;</p><p>The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.</p><p>&nbsp;</p><p>In the case of the following haemorrhagic events, the factor IX activity should not fall below the given plasma activity levels (in % of normal or in IU/dL) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top">&nbsp;<p><strong>Degree of haemorrhage/Type of surgical procedure</strong></p></td><td style="vertical-align:top"><p><strong>Factor IX level required (%) or (IU/dL)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency of doses (hours)/Duration of Therapy (days)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Haemorrhage</strong></p><p>&nbsp;</p><p>Early haemarthrosis, muscle bleeding or oral bleeding</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>20-40</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Repeat every 24&nbsp;hours. At least 1&nbsp;day, until the bleeding episode as indicated by pain is resolved or healing is achieved.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>More extensive haemarthrosis, muscle bleeding or haematoma</p></td><td style="vertical-align:top"><p>30-60</p></td><td style="vertical-align:top"><p>Repeat infusion every 24&nbsp;hours for 3‑4&nbsp;days or more until pain and acute disability are resolved.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Life-threatening haemorrhages</p></td><td style="vertical-align:top"><p>60-100</p></td><td style="vertical-align:top"><p>Repeat infusion every 8 to 24&nbsp;hours until threat is resolved.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Surgery</strong></p><p>&nbsp;</p><p>Minor:</p><p>Including tooth extraction</p><p>&nbsp;</p><p>Major</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>30-60</p><p>&nbsp;</p><p>&nbsp;</p><p>80-100</p><p>(pre- and postoperative)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Every 24&nbsp;hours, at least</p><p>1&nbsp;day, until healing is achieved.</p><p>&nbsp;</p><p>Repeat infusion every 8‑24&nbsp;hours until adequate wound healing, then therapy for at least another 7&nbsp;days to maintain a factor IX activity of 30% to 60% (IU/dL)</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Prophylaxis</u></em></p><p>BeneFIX may be administered for long term prophylaxis against bleeding in patients with &nbsp;haemophilia B. In a clinical study for routine secondary prophylaxis the average dose for previously treated patients (PTP) was 40<strong>&nbsp;</strong>IU/kg (range 13 to 78&nbsp;IU/kg) at intervals of 3 to 4&nbsp;days.</p><p>&nbsp;</p><p>In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.</p><p>&nbsp;</p><p>In other clinical studies in moderately severe to severe haemophilia B (FIX:C &le; 2%) PTPs, BeneFIX was administered as 100&nbsp;IU/kg once weekly.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>There is limited documentation of on-demand treatment and surgery in paediatric patients less than 6&nbsp;years of age treated with BeneFIX.</p><p>&nbsp;</p><p>Mean dosage (&plusmn; standard deviation) for prophylaxis was 63.7&nbsp;(&plusmn;&nbsp;19.1)&nbsp;IU/kg at intervals of 3 to 7&nbsp;days. In younger patients, shorter dosage intervals or higher doses may be necessary. FIX consumption for routine prophylaxis in 22 evaluable patients was 4607&nbsp;(&plusmn;&nbsp;1849)&nbsp;IU/kg per year and 378&nbsp;(&plusmn;&nbsp;152)&nbsp;IU/kg per month.</p><p>&nbsp;</p><p>Close monitoring of factor IX plasma activity should be performed as clinically indicated, as well as calculation of pharmacokinetic parameters such as recovery and half-life, in order to adjust doses as appropriate.</p><p>&nbsp;</p><p><u>Elderly population</u></p><p>Clinical studies of BeneFIX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. As with any patient receiving BeneFIX, dose selection for an elderly patient should be individualised.</p><p><strong>&nbsp;</strong></p><p><u>Method of administration</u></p><p>BeneFIX is administered by intravenous infusion after reconstitution of the lyophilised powder for<strong> </strong>solution for injection with sterile 0.234% sodium chloride solution (see section&nbsp;6.6).</p><p>&nbsp;</p><p>BeneFIX should be administered at a slow infusion rate. In most of the cases, an infusion rate of up to 4&nbsp;mL per minute has been used. The rate of administration should be determined by the patient&rsquo;s comfort level.</p><p><strong>&nbsp;</strong></p><p>If any suspected hypersensitivity reaction takes place that is thought to be related to the administration of BeneFIX, the rate of infusion should be decreased or the infusion stopped (see sections&nbsp;4.4 and&nbsp;4.8).</p><p>&nbsp;</p><p><u>Agglutination of red blood cells in the tube/syringe</u></p><p>There have been reports of agglutination of red blood cells in the tube/syringe with the administration of BeneFIX. No adverse events have been reported in association with this observation. To minimize the possibility of agglutination, it is important to limit the amount of blood entering the tubing. Blood should not enter the syringe. If agglutination of red blood cells in the tubing/syringe is observed, discard all this material (tubing, syringe and BeneFIX solution) and resume administration with a new package.</p><p>&nbsp;</p><p><u>Continuous infusion</u></p><p>Administration by continuous infusion has not been approved and is not recommended (see also sections&nbsp;4.4 and&nbsp;6.6).</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section&nbsp;6.6.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known allergic reaction to hamster proteins.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>Patients can affix one of the peel‑off labels found on the vial to document the batch number in their diary or for reporting any side effects.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Allergic-type hypersensitivity reactions are possible with BeneFIX. The product contains traces of hamster proteins. Potentially life-threatening anaphylactic/anaphylactoid reactions have occurred with factor IX products, including BeneFIX. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of early signs of hypersensitivity reactions including difficult breathing, shortness of breath, swelling, hives, generalised urticaria, itching, tightness of the chest, bronchospasm, laryngospasm, wheezing, hypotension, blurred vision, and anaphylaxis.</p><p>&nbsp;</p><p>In some cases, these reactions have progressed to severe anaphylaxis. In the case of shock, the current medical standards for treatment of shock should be observed. In case of severe allergic reactions, alternative haemostatic measures should be considered.</p><p>&nbsp;</p><p><u>Inhibitors</u></p><p>Inhibitors are an uncommon event in previously treated patients (PTPs) receiving factor IX-containing products. As one PTP treated with BeneFIX developed a clinically relevant low responding inhibitor during clinical studies and experience on antigenicity with recombinant factor IX is still limited, patients treated with BeneFIX should be carefully monitored for the development of factor IX inhibitors that should be titrated in Bethesda Units using appropriate biological testing.</p><p>&nbsp;</p><p>There have been reports in the literature showing a correlation between the occurrence of a factor IX inhibitor and allergic reactions. Therefore, patients experiencing allergic reactions should be evaluated for the presence of an inhibitor. It should be noted that patients with factor IX inhibitors may be at an increased risk of anaphylaxis with subsequent challenge with factor IX. Preliminary information suggests a relationship may exist between the presence of major deletion mutations in a patient&#39;s<em> </em>factor IX gene and an increased risk of inhibitor formation and of acute hypersensitivity reactions. Patients known to have major deletion mutations of the factor IX gene should be observed closely for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of initial exposure to product.</p><p>&nbsp;</p><p>Because of the risk of allergic reactions with factor IX concentrates, the initial administrations of factor IX should, according to the treating physician&rsquo;s judgement, be performed under medical observation where proper medical care for allergic reactions could be provided.</p><p>&nbsp;</p><p><u>Thrombosis</u></p><p>Although BeneFIX contains only factor IX, the risk of thrombosis and disseminated intravascular coagulation (DIC) should be recognised. Since the use of factor IX complex concentrates has historically been associated with the development of thromboembolic complications, the use of factor IX-containing products may be potentially hazardous in patients with signs of fibrinolysis and in patients with disseminated intravascular coagulation (DIC). Because of the potential risk of thrombotic complications, clinical surveillance for early signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing when administering this product to patients with liver disease, to patients post-operatively, to new‑born infants, or to patients at risk of thrombotic phenomena or DIC. In each of these situations, the benefit of treatment with BeneFIX should be weighed against the risk of these complications.</p><p>&nbsp;</p><p>The safety and efficacy of BeneFIX administration by continuous infusion have not been established (see also sections&nbsp;4.2&nbsp;and&nbsp;4.8). There have been post-marketing reports of thrombotic events, including life‑threatening superior vena cava (SVC) syndrome in critically ill neonates, while receiving continuous‑infusion BeneFIX through a central venous catheter (see also section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Cardiovascular events</u></p><p>In patients with existing cardiovascular risk factors, substitution therapy with FIX may increase the cardiovascular risk.</p><p><u>&nbsp;</u></p><p><u>Nephrotic syndrome</u></p><p>Nephrotic syndrome has been reported following attempted immune tolerance induction in haemophilia B patients with factor IX inhibitors and a history of allergic reaction. The safety and efficacy of using BeneFIX for immune tolerance induction has not been established.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>Sufficient data have not been obtained from clinical studies on the treatment of previously untreated patients (PUPs) with BeneFIX.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>After reconstitution, BeneFIX contains 0.2&nbsp;mmol sodium (4.6&nbsp;mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;. Depending on body weight of the patient and posology of BeneFIX, patients could receive multiple vials. This should be taken into consideration if the patient is on a low salt diet.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions of human coagulation factor IX (rDNA) products with other medicinal products have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal reproduction studies have not been conducted with factor IX. Based on the rare occurrence of haemophilia B in women, experience regarding the use of factor IX during pregnancy and breastfeeding is not available. Therefore, factor IX should be used during pregnancy and breast‑feeding only if clearly indicated.</p><p>&nbsp;</p><p>The effect of BeneFIX on fertility has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BeneFIX has no influence on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed and may in some cases progress to severe anaphylaxis (including shock). In some cases, these reactions have progressed to severe anaphylaxis, and they have occurred in close temporal association with development of factor IX inhibitors (see also section&nbsp;4.4). Nephrotic syndrome has been reported following attempted immune tolerance induction in haemophilia B patients with factor IX inhibitors and a history of allergic reaction.</p><p>&nbsp;</p><p>Very rarely development of antibodies to hamster protein with related hypersensitivity reactions has been observed.</p><p>&nbsp;</p><p>Patients with haemophilia B may develop neutralising antibodies (inhibitors) to factor IX. If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.</p><p>&nbsp;</p><p>There is a potential risk of thromboembolic episodes following the administration of factor IX products, see section&nbsp;4.4.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies have been evaluated according to the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), not known (cannot be estimated from the available data). The table lists adverse reactions reported in the clinical trials of previously treated patients and identified in postmarketing use. The frequencies are based on all causality treatment emergent adverse events in pooled clinical trials with 224 subjects.</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><thead><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Very common</p><p>&ge;&nbsp;1/10</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common</p><p>&ge;&nbsp;1/100</p><p>to &lt;&nbsp;1/10</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&ge;&nbsp;1/1,000 to<br />&nbsp;&lt;&nbsp;1/100</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Frequency</p><p>not known</p><p>(cannot be</p><p>estimated from</p><p>the available data)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infusion‑site cellulitis<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Factor IX inhibition<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction*</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache<sup>d</sup></p></td><td style="vertical-align:top"><p>Dizziness;</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Somnolence;</p><p>tremor</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual impairment<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia<sup>f</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phlebitis; flushing<sup>g</sup></p></td><td style="vertical-align:top"><p>Hypotension<sup>h</sup></p></td><td style="vertical-align:top"><p>Superior vena cava syndrome<sup>i,</sup>*<sup> </sup>;<br />deep vein thrombosis*;</p><p>thrombosis*;</p><p>thrombophlebitis*</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Cough<sup>j</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting; nausea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash<sup>k</sup>; urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal infarct<sup>l</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Chest discomfort<sup>o</sup>; infusion‑site reaction<sup>n</sup>; infusion‑site pain<sup>m</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Inadequate therapeutic response*</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Inadequate factor IX recovery<sup> p, </sup>*</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*&nbsp; ADR identified post-marketing</p><p><sup>a</sup>&nbsp; including cellulitis</p><p><sup>b</sup>&nbsp; low-titer transient inhibitor formation</p><p><sup>c</sup>&nbsp; including drug hypersensitivity, angioedema, bronchospasm, wheezing, dyspnoea, and laryngospasm</p><p><sup>d</sup>&nbsp; including migraine, sinus headache</p><p><sup>e</sup>&nbsp; including scintillating scotoma and blurred vision</p><p><sup>f</sup>&nbsp;&nbsp; including heart rate increased, sinus tachycardia</p><p><sup>g</sup>&nbsp; including hot flush, feeling hot, skin warm</p><p><sup>h</sup>&nbsp; including blood pressure decreased</p><p><sup>i</sup>&nbsp;&nbsp; superior vena cava (SVC) syndrome in critically ill neonates, while receiving continuous-infusion of BeneFIX through a central venous catheter</p><p><sup>j</sup>&nbsp;&nbsp; including productive cough</p><p><sup>k</sup>&nbsp; including rash macular, rash papular, rash maculopapular</p><p><sup>l</sup>&nbsp;&nbsp; developed in a hepatitis C antibody-positive patient 12 days after a dose of BeneFIX for a bleeding episode.</p><p><sup>m</sup> including injection site pain, infusion‑site discomfort</p><p><sup>n</sup>&nbsp; including infusion‑site pruritus, infusion‑site erythema</p><p><sup>o</sup>&nbsp; including chest pain and chest tightness</p><p><sup>p</sup>&nbsp; This is a verbatim term. No MedDRA 17.1 PT was retrieved.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em><u>Hypersensitivity/allergic reactions</u></em></p><p>If any suspected hypersensitivity reaction takes place that is thought to be related to the administration of BeneFIX see sections&nbsp;4.2 and&nbsp;4.4.</p><p>&nbsp;</p><p><em><u>Inhibitor development</u></em></p><p>A clinically relevant, low responding inhibitor was detected in 1 out of 65 BeneFIX patients (including 9 patients participating only in the surgery study) who had previously received plasma-derived products. This patient was able to continue treatment with BeneFIX with no anamnestic rise in inhibitor or anaphylaxis (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Allergic reactions might be experienced more frequently in children than in adults.</p><p>&nbsp;</p><p>There are insufficient data to provide information on inhibitor incidence in PUPs (see also section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance and Drug Safety Center (NPC).</p><p>&nbsp;</p><p>To Report side effects:</p><p>&nbsp;</p><p>Saudi Arabia:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; &nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; Fax: +966 11 205 7662</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website:https://ade.sfda.gov.sa/&nbsp;&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No symptoms of overdose have been reported with recombinant coagulation factor IX products.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antihaemorrhagics, blood coagulation factor IX; ATC code: B02BD04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>BeneFIX contains recombinant coagulation factor IX, (nonacog alfa). Recombinant coagulation factor&nbsp;IX is a single chain glycoprotein with an approximate molecular mass of 55,000 Daltons that is a member of the serine protease family of vitamin K‑dependent coagulation factors. Recombinant coagulation factor IX is a recombinant DNA‑based protein therapeutic which has structural and functional characteristics comparable to endogenous factor IX. Factor IX is activated by factor&nbsp;VII/tissue factor complex in the extrinsic pathway as well as factor XIa in the intrinsic coagulation pathway. Activated factor IX, in combination with activated factor VIII, activates factor&nbsp;X. This results ultimately in the conversion of prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Factor IX activity is absent or greatly reduced in patients with haemophilia B and substitution therapy may be required.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Haemophilia B is a sex‑linked hereditary disorder of blood coagulation due to decreased levels of factor IX and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of factor&nbsp;IX is increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Efficacy analysis in study 3090A1-301-WW was based on 22 evaluable paediatric subjects on prophylaxis regimen including 4 on‑demand patients who shortly changed to prophylaxis. Two patients underwent surgical procedures (circumcision and port‑a‑catheter insertion). Safety analysis of 25 evaluable patients reflected a safety profile as expected. The only documented serious adverse event related with BeneFIX was reported from the only included PUP, who experienced hypersensitivity and inhibitor development.</p><p>&nbsp;</p><p><u>Routine Prophylaxis</u></p><p>In an open-label trial of 25 patients (age range 12-54 years) comparing on-demand treatment versus prophylaxis when administered at a dose of 100 IU/kg once weekly, the annualized bleed rate&nbsp;(ABR) for the prophylaxis period was significantly lower (p &lt;&nbsp;0.0001) than the ABR for the on-demand period (mean &plusmn; standard deviation (SD): 3.6 &plusmn; 4.6, median: 2.0, min-max: 0-13.8 versus mean: 32.9 &plusmn; 17.4, median: 33.6, min-max: 6.1-69.0, respectively).</p><p>In an open-label crossover trial in patients aged 6-64 years, of 100 IU/kg once weekly (44&nbsp;patients) and 50 IU/kg twice weekly (43 patients) with 4-month treatment periods, the ABR for the 100 IU/kg once-weekly prophylaxis period was mean 4.4 &plusmn; 10.0 episodes per year (median: 0.0, min-max: 0 &ndash; 50.5) and mean 2.8 &plusmn; 5.7 (median: 0.0, min-max: 0 &ndash; 24.1) for the 50 IU/kg twice-weekly period. Six patients aged &lt;12 years had mean ABR of 1.6 &plusmn; 1.7 (median: 1.5, min-max: 0-3.3) in the 100 IU/kg weekly period, and mean ABR of 0 &plusmn; 0 (median: 0, min-max: 0-0) in the 50 IU/kg twice weekly period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a randomized, cross‑over pharmacokinetic study, BeneFIX reconstituted in 0.234% sodium chloride diluent was shown to be pharmacokinetically equivalent to the previously marketed BeneFIX (reconstituted with sterile water) in 24&nbsp;previously treated patients (&ge;12&nbsp;years) at a dose of 75&nbsp;IU/kg. In addition, pharmacokinetic parameters were followed up in 23&nbsp;of the same patients after repeated administration of BeneFIX for six months and found to be unchanged compared with those obtained at the initial evaluation. A summary of pharmacokinetic data is presented in Table&nbsp;1.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table 1. Pharmacokinetic Parameter Estimates for BeneFIX (75&nbsp;IU/kg) at Baseline and Month&nbsp;6 in Previously Treated Patients with Haemophilia B</p></td></tr><tr><td><p>Parameter</p></td><td style="vertical-align:bottom"><p>Baseline n = 24<br />Mean &plusmn; SD</p></td><td style="vertical-align:bottom"><p>Month&nbsp;6 n = 23<br />Mean &plusmn; SD</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (IU/dL)</p></td><td style="vertical-align:top"><p>54.5 &plusmn; 15.0</p></td><td style="vertical-align:top"><p>57.3 &plusmn; 13.2</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>&infin;</sub> (IU∙hr/dL)</p></td><td style="vertical-align:top"><p>940 &plusmn; 237</p></td><td style="vertical-align:top"><p>923 &plusmn; 205</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub> (hr)</p></td><td><p>22.4 &plusmn; 5.3</p></td><td><p>23.8 &plusmn; 6.5</p></td></tr><tr><td style="vertical-align:top"><p>CL (mL/hr/kg)</p></td><td><p>8.47 &plusmn; 2.12</p></td><td><p>8.54 &plusmn; 2.04</p></td></tr><tr><td style="vertical-align:top"><p>Recovery<br />(IU/dL per IU/kg)</p></td><td><p>0.73 &plusmn; 0.20</p></td><td><p>0.76 &plusmn; 0.18</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Abbreviations: AUC<sub>&infin;</sub> = area under the plasma concentration-time curve from time zero to infinity; C<sub>max</sub> = peak concentration; t<sub>1/2</sub> = plasma elimination half‑life; CL = clearance; SD&nbsp;= standard deviation.</p></td></tr></tbody></table><p>&nbsp;</p><p>A population pharmacokinetic model was developed using data collected in 73 patients aged 7&nbsp;months to 60&nbsp;years. The parameters estimated using the final 2‑compartment model are shown in Table 2. Infants and children had higher clearance, larger volume of distribution, shorter half‑life and lower recovery than adolescents and adults. The terminal phase has not been covered unambiguously due to lack of data beyond 24&nbsp;hours in paediatric subjects &lt;&nbsp;6&nbsp;years of age.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><thead><tr><td colspan="6" style="vertical-align:top"><p><strong>Table 2. Mean </strong><strong>&plusmn; SD Pharmacokinetic Parameters Based on Individual Bayes Estimates from Population Pharmacokinetic Analysis</strong></p></td></tr></thead><tbody><tr><td><p>Age Group (years)</p></td><td><p>Infants</p><p>&lt;2</p></td><td><p>Children</p><p>2 to &lt; 6</p></td><td><p>Children</p><p>6 to &lt; 12</p></td><td><p>Adolescents</p><p>12 to &lt; 18</p></td><td><p>Adults</p><p>18 to 60</p></td></tr><tr><td><p>Number of subjects</p></td><td><p>7</p></td><td><p>16</p></td><td><p>1</p></td><td><p>19</p></td><td><p>30</p></td></tr><tr><td><p>Clearance (mL/h/kg)</p></td><td><p>13.1 &plusmn; 2.1</p></td><td><p>13.1 &plusmn; 2.9</p></td><td><p>15.5</p></td><td><p>9.2 &plusmn; 2.3</p></td><td><p>8.0 &plusmn; 0.6</p></td></tr><tr><td><p>Vss (mL/kg)</p></td><td><p>252 &plusmn; 35</p></td><td><p>257 &plusmn; 25</p></td><td><p>303</p></td><td><p>234 &plusmn; 49</p></td><td><p>225 &plusmn; 59</p></td></tr><tr><td><p>Elimination half‑life (h)</p></td><td><p>15.6 &plusmn; 1.2</p></td><td><p>16.7 &plusmn; 1.9</p></td><td><p>16.3</p></td><td><p>21.5 &plusmn; 5.0</p></td><td><p>23.9 &plusmn; 4.5</p></td></tr><tr><td><p>Recovery (IU/dL per IU/kg)</p></td><td><p>0.61 &plusmn; 0.10</p></td><td><p>0.60 &plusmn; 0.08</p></td><td><p>0.47</p></td><td><p>0.69 &plusmn; 0.16</p></td><td><p>0.74 &plusmn; 0.20</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Non‑clinical data reveal no special hazard for humans based on conventional studies of genotoxicity.</p><p>&nbsp;</p><p>No investigations on carcinogenicity, fertility impairment and foetal development have been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Sucrose 10mg/ml</p><p>Glycine 19.50mg/ml</p><p>L‑Histidine&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.55mg/ml</p><p>Polysorbate 80 0.054 mg/ml</p><p><strong>&nbsp;</strong></p><p><u>Solvent</u></p><p>Sodium chloride solution</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Only the provided infusion set should be used. Treatment failure can occur as a consequence of human coagulation factor IX adsorption to the internal surfaces of some infusion equipment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
Do not use BeneFIX after the expiry date which is stated on the Vial label after EXP:. The expiry date refers to the last day of that month.

The reconstituted product does not contain a preservative and should be used immediately, but no longer than 3 hours after reconstitution. Chemical and physical in-use stability has been demonstrated for 3 hours at temperatures up to 25oC.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benefix must be stored continuously in a refrigerator at a temperature of 2&deg;C to 8&deg;C and must be used by the expiry date on the label</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>BeneFIX 250 IU powder and solvent for solution for injection</u>: 250&nbsp;IU of powder in a 10&nbsp;ml vial (type 1 glass) with a stopper (chlorobutyl) and a flip-off seal (aluminium) and 5&nbsp;ml of clear, colourless solvent in a prefilled syringe (type 1 glass) with a plunger stopper (bromobutyl), a tip-cap (bromobutyl) and a sterile vial adapter reconstitution device, a sterile infusion set, two alcohol swabs, a plaster, and a gauze pad.</p><p>&nbsp;</p><p>BeneFIX 500 IU powder and solvent for solution for injection: 500&nbsp;IU of powder in a 10&nbsp;ml vial (type 1 glass) with a stopper (chlorobutyl) and a flip-off seal (aluminium) and 5&nbsp;ml of clear, colourless solvent in a prefilled syringe (type 1 glass) with a plunger stopper (bromobutyl), a tip-cap (bromobutyl) and a sterile vial adapter reconstitution device, a sterile infusion set, two alcohol swabs, a plaster, and a gauze pad.</p><p>&nbsp;</p><p>BeneFIX 1000 IU powder and solvent for solution for injection: 1000&nbsp;IU of powder in a 10&nbsp;ml vial (type 1 glass) with a stopper (chlorobutyl) and a flip-off seal (aluminium) and 5&nbsp;ml of clear, colourless solvent in a prefilled syringe (type 1 glass) with a plunger stopper (bromobutyl), a tip-cap (bromobutyl) and a sterile vial adapter reconstitution device, a sterile infusion set, two alcohol swabs, a plaster, and a gauze pad.</p><p>&nbsp;</p><p>BeneFIX 2000 IU powder and solvent for solution for injection: 2000&nbsp;IU of powder in a 10&nbsp;ml vial (type 1 glass) with a stopper (chlorobutyl) and a flip-off seal (aluminium) and 5&nbsp;ml of clear, colourless solvent in a prefilled syringe (type 1 glass) with a plunger stopper (bromobutyl), a tip-cap (bromobutyl) and a sterile vial adapter reconstitution device, a sterile infusion set, two alcohol swabs, a plaster, and a gauze pad.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>BeneFIX is administered by intravenous infusion after reconstitution of the lyophilised powder for injection with the supplied solvent (0.234% w/v sodium chloride solution) in the pre‑filled syringe (see also section&nbsp;3 of the package leaflet for reconstitution instructions).</p><p><strong>&nbsp;</strong></p><p>BeneFIX, when reconstituted, contains polysorbate‑80, which is known to increase the rate of di‑(2‑ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of BeneFIX. It is important that the recommendations in section&nbsp;4.2 be followed closely.</p><p><strong>&nbsp;</strong></p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Because the use of BeneFIX by continuous infusion has not been evaluated, BeneFIX should not be mixed with infusion solutions or be given in a drip.</p><p>&nbsp;</p><p><strong>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER 

Wyeth Farma S.A.
Autovia Del Norte A-1 KM. 23.Desvio Algete, KM, 1, 28700 S. Sebastian DE
Los Reyes Madrid 
Spain 

MANUFACTURING, PACKAGING & RELEASE BY:

Wyeth Farma S.A.
Autovia Del Norte A-1 KM. 23.Desvio Algete, KM, 1, 28700 S. Sebastian DE
Los Reyes Madrid 
Spain 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EU: November 2020

USPI: June 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>